



Disclosure of total number of voting rights and number of shares in the capital at September 30, 2009

Paris, October 9, 2009 – Pursuant to article L.233-8 II of the *Code de commerce* (the French Commercial Code) and article 233-16 of the *Règlement général de l’Autorité des Marchés Financiers* (Regulation of the French stock market authority):

Date	Total number of outstanding shares	Total number of voting rights
September 30, 2009	12, 896,834	Theoretical number of voting rights: 12, 896,834 (including treasury shares) Number of real voting rights: 12, 871, 808 (without treasury shares)

About BioAlliance Pharma

BioAlliance Pharma SA is a company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues.

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com